Trial Profile
A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination With Pomalidomide and Low-Dose Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Belantamab mafodotin (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ALGONQUIN
- Sponsors GlaxoSmithKline; GSK
- 01 Feb 2024 Results(n=87) for safety and efficacy published in the Nature Medicine
- 16 Jan 2024 According to Canadian Myeloma Research Group Media Release, data from the study were presented at Nature Medicine.
- 16 Jan 2024 Results presented in the Canadian Myeloma Research Group Media Release